Checkpoint Therapeutics I...

AI Score

0

Unlock

3.14
-0.06 (-1.88%)
At close: Jan 14, 2025, 3:59 PM
3.09
-1.59%
After-hours Jan 14, 2025, 05:14 PM EST
undefined%
Bid 3.03
Market Cap 151.14M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.83
PE Ratio (ttm) -1.72
Forward PE n/a
Analyst Buy
Ask 3.6
Volume 829,593
Avg. Volume (20D) 1,485,240
Open 3.23
Previous Close 3.20
Day's Range 3.13 - 3.35
52-Week Range 1.38 - 4.50
Beta undefined

About CKPT

Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-...

Industry Biotechnology
Sector Healthcare
IPO Date Dec 19, 2016
Employees 23
Stock Exchange NASDAQ
Ticker Symbol CKPT

Analyst Forecast

According to 3 analyst ratings, the average rating for CKPT stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 186.62% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
6 months ago · Source
+15.56%
Checkpoint Therapeutics shares are trading higher ... Unlock content with Pro Subscription